medigraphic.com
SPANISH

Biotecnología Aplicada

ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2013, Number 1

<< Back

Biotecnol Apl 2013; 30 (1)

II International congress addressed to the integral care of diabetic foot ulcer patient with the use of Heberprot-P 2012: healthy doorways wide-open to the 2014 edition

Raíces M
Full text How to cite this article

Language: English
References: 2
Page: 63-64
PDF size: 78.31 Kb.


Key words:

Heberprot-P, pharmaceutical development, epidermal growth factor, infiltration, diabetes mellitus, diabetic foot ulcer, amputation.

ABSTRACT

The second edition of the international congress addressed to the Integral care of diabetic foot patient with the use of Heberprot-P was successfully celebrated last December 12-14th, at the Memories Varadero hotel, in Cuba. Up to 500 delegates from 37 countries attended and were pleased with the update in the treatment of diabetic foot ulcers (DFUs) with Heberprot-P and strategies for the integral care of diabetic patients. The meeting counted on with several world leaders in DFU treatment. During the three working days, 11 plenary lectures, 31 oral presentations and 130 posters were discussed. Main topics comprised the mechanisms of wound healing using the human epidermal growth factor and its safety for DFU therapy. The use of Heberprot-P in Cuban patients as part of the nationwide integral care program for the treatment of DFUs was highlighted. This program have been extended to 43 major hospitals and 197 local clinics, with more than 15 000 patients treated and diminishing amputation rates in more than 65 %. This is a remarkable result considering that Heberprot-P successfully targets and generally cicatrizes complex Wagner 3-5 ulcers, mainly ischemic.


REFERENCES

  1. Global diabetes market breakout. 2010. Foothill Ranch: MedMarket Diligence, LLC; c2001-2012 [cited 2012 Dec 23]. Available from: http://mediligence. com/

  2. López-Mola E. Heberprot-P®: an idea turned into a product. Biotecnol Apl. 2012;29(4):262-5.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Biotecnol Apl. 2013;30